A new meta-analysis of phase 3 trials finds that GLP-1 receptor agonists—drugs such as Ozempic, Wegovy, and newer multi-hormone receptor modulators (MHRMs)—are associated with meaningful reductions in blood pressure, both through weight loss and by mechanisms independent of weight change.
Study overview
– Researchers pooled data from 32 phase 3 trials including 43,618 adults with overweight or obesity (average age 54, mean BMI 35.5). About half were women and roughly 9.2% had type 2 diabetes. Some 59% had high blood pressure, and the average treatment period was about 66 weeks.
– After adjusting for placebo, participants lost about 10.9% of body weight on average and experienced a mean systolic blood pressure decrease of 5.2 mmHg.
– The analysis estimated that roughly 77% of the variation in blood-pressure change could be explained by weight loss, corresponding to an average 0.34 mmHg reduction in systolic pressure for each 1% of weight lost. That said, blood-pressure benefits were also seen beyond what weight loss alone would predict.
What this suggests
– Weight loss appears to be the primary driver of lower blood pressure with GLP-1 therapies, but these agents also appear to have direct effects that can reduce blood pressure independently of weight change.
– Investigators propose several non–weight-loss mechanisms that may contribute: increased kidney sodium excretion, improved endothelial and vascular function, reduced arterial stiffness, and modulation of sympathetic nervous system activity. Reduction in chronic inflammation may also play a role.
Perspectives from clinicians
– Marcel Muskiet, MD, PhD, an internist and endocrinologist at Leiden University Medical Center, notes that because obesity and hypertension commonly coexist and jointly raise cardiovascular and kidney risk, effective obesity treatment should be viewed as an important component of blood-pressure and cardiovascular-risk management. He emphasizes that GLP-1 therapies may have renal, vascular, and neurohormonal effects beyond simply causing weight loss.
– Mir Ali, MD, a bariatric surgeon and bariatric medicine specialist, echoes that the results reinforce the link between obesity and hypertension and the potential broader health benefits of treating excess weight.
Cautions and context
– The meta-analysis was presented at the European Congress on Obesity but has not yet undergone peer review in a journal, and the authors acknowledge limitations that warrant further study.
– GLP-1 drugs were developed initially for type 2 diabetes and have become widely used for weight management. Emerging evidence also links them to other potential benefits—improvements in cardiovascular markers, kidney outcomes, cognitive measures, and some observational findings involving cancer outcomes—though more research is needed to define those effects and their mechanisms.
Bottom line
GLP-1–based therapies can lower systolic blood pressure substantially, mostly through weight loss but also via weight-independent biological effects. These findings support considering obesity treatment as part of an integrated strategy to manage blood pressure and reduce cardiovascular risk, while recognizing the need for further peer-reviewed research. Patients should discuss treatment options and blood-pressure goals with their clinician.
